OKYO Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
OKYO Pharma Ltd. furnished this Form 6-K on May 15, 2023. The filing concerns the timing of the company’s planned delisting from the standard segment of the FCA Official List and from trading on the London Stock Exchange Main Market. The company files annual reports on Form 20-F.
Key Financial and Operating Metrics
This filing is administrative and does not provide revenue, profit, cash flow, margin, debt, liquidity, cash balance, or other financial metrics.
Material Change Versus Prior Announcement
- The previously announced delisting date of May 12, 2023 was changed.
- The delisting of the company’s ordinary shares will now take place on Monday, May 22, 2023.
- The stated reason for the change is to facilitate late transfers of certificated positions into CREST before the delisting.
Outlook, Risks, and Unusual Items
The filing provides no financial guidance or operating outlook. Investors should note that, after May 22, 2023, the ordinary shares are expected to cease trading on the LSE Main Market and to be cancelled from the FCA Official List. The filing does not describe any alternative trading venue, liquidity arrangements, or consequences for holders who do not complete transfers into CREST.
Investor Verification Checklist
- Verify that the delisting occurred on May 22, 2023, rather than the previously announced May 12 date.
- Confirm the status of any certificated share positions and required CREST transfer procedures.
- Review Exhibit 99.1 for the detailed announcement and any additional shareholder instructions.
- Determine whether the company provided a continuing trading venue or liquidity option after delisting.